文献速递贫血与红细胞疾病

luspatercept治疗输血依赖型β地中海贫血患者贫血的长期疗效与安全性(BELIEVE):3期随机试验最终结果

Long-term efficacy and safety of luspatercept for the treatment of anaemia in patients with transfusion-dependent β-thalassaemia (BELIEVE): final results from a phase 3 randomised trial.
PubMed 文献 · Lancet Haematol · 2025-02-10

BELIEVE是一项在15个国家65个中心开展的3期随机双盲安慰剂对照研究,纳入336例输血依赖型β地中海贫血成人患者,按2:1随机接受luspatercept(1·0-1·25 mg/kg,每21天皮下注射一次)或安慰剂。长期随访约3年显示,luspatercept组输血负担较基线持续下降,任意12周区间内173例(77%)患者输血负担降低≥33%,安全性总体可控。

要点

  • luspatercept组任意12周区间内173例(77%)患者输血负担较基线降低≥33%。
  • luspatercept组第97-144周红细胞输注量较基线平均减少6·2单位(SD 5·7)。
  • 最常见≥3级治疗中出现的不良事件为贫血9例(3%)、肝铁浓度升高7例(2%)、骨痛7例(2%)。

核心结论

  • 长期结果证实luspatercept对输血依赖型β地中海贫血患者具有疗效,安全性可控。

研究设计与样本

  • 3期随机双盲安慰剂对照研究,在15个国家65个中心开展,336例输血依赖型β地中海贫血或血红蛋白E/β地中海贫血成人患者按2:1随机分配至luspatercept组(n=224)或安慰剂组(n=112)。
  • luspatercept按1·0-1·25 mg/kg每21天皮下注射一次;揭盲后可进入开放标签扩展期并允许交叉。
  • 截至2021年1月5日,luspatercept组中位治疗持续时间153·6周(IQR 81·0-171·0),中位研究随访163·1周(140·5-176·2)。

主要发现

  • luspatercept组红细胞输注负担自基线持续降低至第192周,第97-144周平均减少6·2单位(SD 5·7),第145-192周平均减少6·4单位(SD 4·3)。
  • luspatercept组任意12周区间内173例(77%)患者输血负担较基线降低≥33%,任意24周区间内116例(52%)患者达到该降幅。
  • 任意至少12周期间输血负担降低≥33%的中位总缓解持续时间为586·0天(IQR 264·0-1010·0)。
  • 接受luspatercept的全部患者(n=315,含揭盲后交叉的92例)中最常见≥3级治疗中出现的不良事件为贫血9例(3%)、肝铁浓度升高7例(2%)、骨痛7例(2%);严重治疗中出现的不良事件发生于71例(23%)。
  • 研究期间各组均无治疗相关死亡。

关键数值与推荐

  • 主要终点为第13-24周输血负担降低≥33%且≥2个红细胞单位的患者比例,其结果另文报告,本文报告因迟报输血事件而更新的主要终点分析。
  • 第96周后因两组治疗持续时间不同,未进行两组间比较分析。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 第96周后因luspatercept组与安慰剂组治疗持续时间不同,未进行两组间比较分析。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Treatments to reduce red blood cell (RBC) transfusion burden among patients with transfusion-dependent β-thalassaemia remain limited. Here, we report long-term follow-up data from the phase 3 BELIEVE trial of luspatercept for transfusion-dependent β-thalassaemia. METHODS: BELIEVE was a phase 3, randomised, double-blind, placebo-controlled study performed at 65 sites in 15 countries. The trial included adults with transfusion-dependent β-thalassaemia or haemoglobin E/β-thalassaemia and Eastern Cooperative Oncology Group score of 0-1. Patients were randomly assigned (2:1) using integrated response technology stratified by region to luspatercept (1·0-1·25 mg/kg) or placebo administered subcutaneously once every 21 days. After study unblinding, patients could receive luspatercept in the open-label extension phase (crossover allowed). The primary endpoint results (proportion of patients with reduction in transfusion burden of ≥33% and ≥2 RBC units during weeks 13-24) are described elsewhere; herein we present an update to the primary endpoint analysis consequent to late-reported transfusion events. We also report long-term efficacy (intention-to-treat population) and safety data (safety population) for patients followed up for approximately 3 years. This trial is registered on ClinicalTrials.gov (NCT02604433) and is completed. FINDINGS: Between May 2, 2016, and May 16, 2017, 336 patients were randomly assigned to luspatercept (n=224) or placebo (n=112). The median age of patients was 30 years (IQR 23-40); 195 (58%) were female and 141 (42%) male. As of Jan 5, 2021, the median duration of treatment in the luspatercept group was 153·6 weeks (IQR 81·0-171·0) and median study follow-up was 163·1 weeks (140·5-176·2). Due to the difference in treatment duration between the luspatercept and placebo groups, no comparative analyses between the two groups were performed after week 96. Patients in the luspatercept group showed a sustained reduction in RBC transfusion burden from baseline through week 192, with mean decreases of 6·2 RBC units (SD 5·7) during weeks 97-144 and 6·4 RBC units (4·3) during weeks 145-192. In the luspatercept group, a 33% or greater reduction in transfusion burden from baseline was observed in 173 (77%) patients over any 12-week interval and in 116 (52%) patients over any 24-week interval. The median total duration of 33% or greater transfusion burden reduction response during any period of at least 12 weeks was 586·0 days (IQR 264·0-1010·0). The most common grade 3 or worse treatment-emergent adverse events (TEAEs) among all patients who received luspatercept (n=315, including 92 patients who crossed over after study unblinding) were anaemia (nine [3%]), increased liver iron concentration (seven [2%]), and bone pain (seven [2%]); serious TEAEs occurred in 71 (23%) patients. No treatment-related deaths occurred in any group during the study. INTERPRETATION: These long-term results affirm luspatercept's efficacy in addressing key unmet needs of patients with transfusion-dependent β-thalassaemia with a manageable safety profile. FUNDING: Celgene and Acceleron Pharma.

来源:Lancet Haematol,查看原文。版权归原作者所有。

引用

  1. Cappellini MD, Viprakasit V, Georgiev P, et al. Long-term efficacy and safety of luspatercept for the treatment of anaemia in patients with transfusion-dependent β-thalassaemia (BELIEVE): final results from a phase 3 randomised trial. Lancet Haematol. 2025. PMID: 39947215. doi:10.1016/S2352-3026(24)00376-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。